For the quarter ending 2025-09-30, MLYS made $45,330K in revenue. -$36,932K in net income. Net profit margin of -81.47%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 31,450 | 38,278 | ||
| General and administrative | 9,681 | 8,468 | ||
| Total operating expenses | 41,131 | 46,746 | ||
| Loss from operations | -41,131 | -46,746 | ||
| Interest income, net | 4,195 | 3,474 | ||
| Other income (expense) | 4 | -2 | ||
| Total other income, net | 4,199 | 3,472 | ||
| Net loss | -36,932 | -43,274 | ||
| Net loss per share attributable to common stockholders - basic (in usd per share) | -0.52 | -0.66 | ||
| Net loss per share attributable to common stockholders - diluted (in usd per share) | -0.52 | -0.66 | ||
| Weighted-average shares used to compute net loss per share attributable to common stockholders - basic (in shares) | 70,594,504 | 65,451,297 | ||
| Weighted-average shares used to compute net loss per share attributable to common stockholders - diluted (in shares) | 70,594,504 | 65,451,297 | ||
Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS)